Robeco Institutional Asset Management B.V. Cuts Holdings in Becton, Dickinson and Company $BDX

Robeco Institutional Asset Management B.V. cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 51.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,508 shares of the medical instruments supplier’s stock after selling 15,595 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Becton, Dickinson and Company were worth $2,715,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the last quarter. Empowered Funds LLC raised its stake in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after acquiring an additional 1,354 shares during the period. Integrity Alliance LLC. acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $269,000. Modern Wealth Management LLC lifted its holdings in Becton, Dickinson and Company by 44.4% in the 1st quarter. Modern Wealth Management LLC now owns 1,321 shares of the medical instruments supplier’s stock worth $303,000 after buying an additional 406 shares in the last quarter. Finally, First Hawaiian Bank raised its position in shares of Becton, Dickinson and Company by 27.0% in the 1st quarter. First Hawaiian Bank now owns 4,298 shares of the medical instruments supplier’s stock valued at $984,000 after purchasing an additional 913 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on BDX. Argus lifted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Royal Bank Of Canada increased their price objective on Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Jefferies Financial Group boosted their target price on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Finally, Bank of America boosted their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Four equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $207.64.

Becton, Dickinson and Company Trading Down 1.2%

Shares of BDX stock opened at $202.78 on Friday. The firm has a fifty day moving average of $193.11 and a 200-day moving average of $188.24. The stock has a market cap of $57.77 billion, a price-to-earnings ratio of 34.78, a P/E/G ratio of 2.24 and a beta of 0.23. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is 72.04%.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the transaction, the executive vice president owned 13,105 shares of the company’s stock, valued at approximately $2,568,973.15. The trade was a 4.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 1,052 shares of company stock worth $201,235. Company insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.